SCHEDULE 13D/A: Casdin Capital Boosts Stake in Standard BioTools, Signals Strategic Influence Post-SomaLogic Merger

Casdin Capital and its affiliates have increased their beneficial ownership in Standard BioTools Inc. to 20.4%, with Eli Casdin holding 21.6%, following recent share acquisitions and the conversion of preferred stock, reinforcing their strategic investment in the company after its merger with SomaLogic.

Summary

• Casdin Capital, LLC and its affiliated entities, including Casdin Private Growth Equity Fund II, L.P., Casdin Private Growth Equity Fund II GP, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, and Eli Casdin, have filed an Amendment No. 6 to Schedule 13D regarding their ownership in Standard BioTools Inc.
• As of the filing date, Casdin Capital, LLC beneficially owns 76,075,636 shares, representing 20.4% of Standard BioTools' Common Stock.
• Eli Casdin, a member of the Issuer's Board of Directors, beneficially owns 80,864,315 shares, constituting 21.6% of the Common Stock.
• Casdin Partners Master Fund, L.P. holds 59,391,780 shares (15.9%), while Casdin Private Growth Equity Fund II, L.P. and its GP hold 13,939,637 shares (3.7%), noting they have ceased to be beneficial owners of more than five percent.
• The Reporting Persons initially invested in Standard BioTools (then Fluidigm Corporation) on January 23, 2022, through the purchase of Series B-1 Convertible Preferred Stock for $112,500,000 cash and term loans totaling $12,500,000, which were converted into additional Series B-1 Preferred Stock.
• On March 18, 2024, Casdin PMF and Casdin PGEII exchanged their Series B-1 Preferred Stock for Common Stock, converting 89,446 shares of preferred stock into 32,525,821 common shares for Casdin PMF, and 38,334 preferred shares into 13,939,637 common shares for Casdin PGEII.
• Recent transactions on February 28, 2025, include Casdin PMF acquiring 545,000 Common Stock via a cross-trade and an additional 4,820,959 Common Stock, both at $1.065 per share.
• Eli Casdin also received 58,215 Restricted Stock Units (RSUs) on February 28, 2025, at a price of $0, in lieu of $62,000 in cash compensation for his board service; these RSUs vest quarterly throughout 2025.
• The Issuer completed its merger with SomaLogic, Inc. on January 5, 2024, where each SomaLogic common stock was converted into 1.11 shares of Standard BioTools Common Stock.
• The Reporting Persons acquired their shares for investment purposes and intend to review their holdings continuously, reserving the right to adjust their investment based on various factors.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of ownership and intentions. The significant and increasing stake by a major investor, coupled with the stated intent to potentially influence strategic corporate actions, suggests a moderately positive outlook from the investor's perspective, implying belief in future value creation.

Positives

• Significant and increasing ownership by Casdin Capital and Eli Casdin, indicating strong investor confidence and a long-term strategic interest in Standard BioTools Inc.
• Eli Casdin's position on the Board of Directors provides direct influence and oversight, aligning investor and company interests.
• The Reporting Persons' stated intent to review holdings and potentially increase investment suggests a positive outlook on the Issuer's future prospects.
• The flexibility of the Reporting Persons to encourage strategic actions, such as sales or acquisitions, changes to capitalization, or board structure, could lead to value-enhancing initiatives for the company.
• The conversion of preferred stock to common stock by Casdin PMF and Casdin PGEII simplifies the capital structure and demonstrates a commitment to the common equity.

Risks

• The Reporting Persons reserve the right to change their investment plans at any time, which could lead to significant sales of shares and potential downward pressure on the stock price.
• Future investment decisions are subject to various factors including the Issuer's financial condition, business prospects, general stock market and economic conditions, and alternative investment opportunities, introducing uncertainty.
• The potential for the Reporting Persons to encourage significant corporate actions, such as mergers or changes to capitalization, could introduce volatility or uncertainty for existing shareholders if not executed favorably.

Future Outlook

The Reporting Persons intend to continuously review their holdings in Standard BioTools Inc. and may increase or decrease their investments based on various factors including the Issuer's business prospects, market conditions, and alternative investment opportunities. They also reserve the right to encourage the Issuer to consider significant strategic actions such as sales or acquisitions of assets or businesses, changes to capitalization or dividend policy, modifications to the Board of Directors, or alterations to the Issuer's by-laws and overall business structure. They may also act in concert with other shareholders for common purposes.

Industry Context

This filing highlights a significant investor's continued and evolving stake in Standard BioTools Inc., a company operating in the biotechnology and life sciences sector. The recent merger with SomaLogic Inc. indicates a strategic consolidation within the industry, aiming to leverage combined capabilities. Casdin Capital's deep involvement, including a board seat, suggests a focus on long-term value creation and potential for further strategic maneuvers in a dynamic and innovation-driven market.

Corporate Governance

Related Party Transactions

• On January 23, 2022, Casdin PMF and Casdin PGEII (affiliates of Eli Casdin, a board member) purchased Series B-1 Convertible Preferred Stock for $112,500,000 and provided term loans totaling $12,500,000 to Standard BioTools Inc.
• On March 18, 2024, Casdin PMF and Casdin PGEII exchanged their Series B-1 Preferred Stock for Common Stock of Standard BioTools Inc.
• On February 28, 2025, Eli Casdin, a board member, received 58,215 Restricted Stock Units (RSUs) at a price of $0, in lieu of $62,000 in cash compensation for his services as a board member.

Stakeholder Impact

• **Shareholders:** Increased beneficial ownership by a major investment firm and board member could signal confidence, potentially stabilizing or increasing share price. However, the reservation of rights to sell or influence corporate actions introduces potential volatility.
• **Management:** Eli Casdin's board presence and the Reporting Persons' stated intent to encourage strategic changes could lead to increased scrutiny or pressure on management to align with investor objectives.
• **Employees:** Potential strategic changes like sales or acquisitions of assets/businesses could impact employee roles, departments, or overall company structure.
• **Creditors:** Changes to the Issuer's capitalization or dividend policy, if encouraged by the Reporting Persons, could affect the company's financial leverage and ability to service debt.
• **Customers/Suppliers:** Strategic shifts, such as mergers or divestitures, could alter product offerings, service delivery, or supply chain relationships.

Next Steps

• Reporting Persons will continue to review their holdings in Standard BioTools Inc. on an ongoing basis.
• Reporting Persons may consider increasing or decreasing their investments in the Issuer's securities.
• Reporting Persons may acquire or dispose of Issuer Securities in the open market, privately negotiated transactions, or through derivatives/hedging.
• Reporting Persons may encourage the Issuer to consider sales or acquisitions of assets/businesses, changes to capitalization or dividend policy, changes to the Board of Directors, or changes to the Issuer's by-laws and structure.
• Reporting Persons reserve the right to act in concert with other shareholders for a common purpose.

Key Dates

Keywords

Standard BioTools Inc., Casdin Capital, SEC Schedule 13D, Beneficial Ownership, SomaLogic Merger, Biotechnology, Life Sciences, Investment, Preferred Stock Conversion, Equity Awards, Corporate Governance